TNF and rheumatoid arthritis: Results from BALANCE 1 and BALANCE 2 [84,183], enrolling anti-TNF failing and MTX-failing patients respectively, showed rapid, dose-dependent improvements in RA signs and symptoms, with a similar safety and tolerability profile to those of other JAKi.